Argatroban as novel therapy for suspected thrombosis in patients with continuous-flow left ventricle assist device and hemolysis

ASAIO Journal

Volumn 60, Issue 3, 2014, Pages 361-365

  Badiye, Amit ^a   Hernandez, Gabriel A ^b   Chaparro, Sandra ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b JACKSON MEMORIAL HOSPITAL   (United States)

Author keywords

Anticoagulation; heart; heart failure; thrombosis; ventricle assist device

Indexed keywords

BLOOD; BLOOD VESSELS; CARDIOLOGY; DISEASES; ENZYMES; FIBER OPTIC SENSORS; HEART; LEFT VENTRICULAR ASSIST DEVICES;

ANTI-COAGULATION; ASSIST DEVICE; DESTINATION THERAPY; DIRECT THROMBIN INHIBITOR; HEART FAILURE; LACTATE DEHYDROGENASE; LEFT VENTRICULAR; THROMBOSIS;

PATIENT TREATMENT;

ACETYLSALICYLIC ACID; ARGATROBAN; CLOPIDOGREL; DIPYRIDAMOLE; DOXORUBICIN; HEPARIN; LACTATE DEHYDROGENASE; WARFARIN; ANTICOAGULANT AGENT; ANTITHROMBIN; PIPECOLIC ACID DERIVATIVE; THROMBIN;

ACUTE HEART FAILURE; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ARTICLE; BLEEDING; CASE REPORT; CATHETER INFECTION; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS FLOW LEFT VENTRICULAR ASSIST DEVICE; DEVICE REMOVAL; DEVICE THROMBOSIS; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RIGHT VENTRICLE FAILURE; HEMOLYSIS; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; INTRAAORTIC BALLOON PUMP; MALE; MEDICAL DEVICE COMPLICATION; MIDDLE AGED; MITRAL VALVE REGURGITATION; MITRAL VALVE REPAIR; NONISCHEMIC CARDIOMYOPATHY; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; SUBDURAL HEMATOMA; THORAX RADIOGRAPHY; THROMBOPLASTIN TIME; THROMBOSIS; URINE COLOR; ANTAGONISTS AND INHIBITORS; CARDIOMYOPATHIES; HEART ASSIST DEVICE; HEART FAILURE; HEART VENTRICLE; PATHOPHYSIOLOGY;

ADULT; AGED; ANTICOAGULANTS; ANTITHROMBINS; CARDIOMYOPATHIES; FEMALE; HEART FAILURE; HEART VENTRICLES; HEART-ASSIST DEVICES; HEMOLYSIS; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PIPECOLIC ACIDS; THROMBIN; THROMBOSIS;

EID: 84900465401     PISSN: 10582916     EISSN: 1538943X     Source Type: Journal    
DOI: 10.1097/MAT.0000000000000067     Document Type: Article

References (15)

1. Rossi M, Serraino GF, Jiritano F, Renzulli A: What is the optimal anticoagulation in patients with a left ventricular assist device Interact Cardiovasc Thorac Surg 15: 733 -740, 2012.
2. Feldman D, Pamboukian SV, Teuteberg JJ, et al; International Society for Heart and Lung Transplantation: The 2013 International Society for Heart and Lung Transplantation Guidelines for mechanical circulatory support: Execut ive summary. J Heart Lung Transplant 32: 157- 187, 2013.
3. Hasin T, Marmor Y, Kremers W, et al: Readmissions after implantation of axial flow left ventricular assist device. J Am Coll Cardiol 61: 153 -163, 2013.
4. Moazami N, Milano CA, John R, et al; HeartMate II Investigators: Pump replacement for left ventricular assist device failure can be done safely and is associated with low mortality. Ann Thorac Surg 95: 500-505, 2013.
5. Starling RC, Moazami N, Silvestry SC, et al: Unexpected abrupt increase in left ventricular assist device thrombosis. N Engl J Med 370: 33 -40, 2014.
6. Goldstein DJ, John R, Salerno C, et al: Algorithm for the diagnosis and management of suspected pump thrombus. J Heart Lung Transplant 32: 667- 670, 2013.
7. Hayes H, Dembo L, Larbalestier R, O?Driscoll G: Successful treatment of ventricular assist device associated ventricular thrombus with systemic tenecteplase. Heart Lung Circ 17: 253-25 5, 2008.
8. Ballew CC, Benton EM, Groves DS, et al: Comparing survival of HMII patients with elevated LDH: Implications for medical and surgical management. J Heart Lung Transplant 32: s38, 2013.
9. Swan SK, Hursting MJ: The pharmacokinetics and pharmacodynamics of argatroban: Effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 20: 318-329, 2000.
10. Goldstein DJ, Beauford RB: Left ventricular assist devices and bleeding: Adding insult to injury. Ann Thorac Surg 75(6 suppl): S42-S47, 2003.
11. Reilly MP, Wiegers SE, Cucchiara AJ, et al: Frequency, risk factors, and clinical outcomes of left ventricular assist device-associated ventricular thrombus. Am J Cardiol 86: 1156 -1159, A10, 2000.
12. Peura JL, Colvin-Adams M, Francis GS, et al; American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology; Council on Cardiopulmonary, Critical Care, Perioper ative and Resuscitation; Council on Cardiovascular Disease in the Young; Council on Cardiovascular Nursing; Council on Cardiovascular Radiology and Intervention, and Council on Cardiovascular Surgery and Anesthesia: Recommendations for the use of mechanic al circulatory support: Device strategies and patient selection: A scientific statement from the American Heart Association. Circulation 126: 2648 -2667, 2012.
13. Berry CN, Girardot C, Lecoffre C, Lunven C: Effects of the synthetic thrombin inhibitor argatroban on fibrin-or clot-incorporated thrombin: Comparison with heparin and recombinant Hirudin. Thromb Haemost 72: 381-386, 1994.
14. Pappalardo F,Scandroglio AM,Potapov E,et al, Argatroban anticoagulation for heparin induced thrombocytopenia in patients with ventricular assist devices. Minerva Anestesiol, 78, 330-335, 2012.
15. Sheth SB, DiCicco RA, Hursting MJ, Montague T, Jorkasky DK: Interpreting the International Normalized Ratio (INR) in individuals receiving argatroban and warfarin. Thromb Haemost 85: 435-440, 2001.